vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Solowin Holdings, Ltd. is the larger business by last-quarter revenue ($410.0K vs $284.0K, roughly 1.4× Dianthus Therapeutics, Inc.). Solowin Holdings, Ltd. produced more free cash flow last quarter ($-1.6M vs $-47.1M).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
AXG vs DNTH — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $284.0K |
| Net Profit | — | $-64.4M |
| Gross Margin | — | — |
| Operating Margin | -34.1% | -24486.3% |
| Net Margin | — | -22687.3% |
| Revenue YoY | — | -78.6% |
| Net Profit YoY | — | -126.6% |
| EPS (diluted) | — | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $284.0K | ||
| Q3 25 | — | $396.0K | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $1.3M | ||
| Q3 24 | $410.0K | $2.2M | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $874.0K | ||
| Q3 23 | — | $924.0K |
| Q4 25 | — | $-64.4M | ||
| Q3 25 | — | $-36.8M | ||
| Q1 25 | — | $-29.5M | ||
| Q4 24 | — | $-28.4M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | — | $-17.6M | ||
| Q1 24 | — | $-13.7M | ||
| Q3 23 | — | $-14.8M |
| Q4 25 | — | -24486.3% | ||
| Q3 25 | — | -10173.7% | ||
| Q1 25 | — | -2852.7% | ||
| Q4 24 | — | -2406.9% | ||
| Q3 24 | -34.1% | -1376.6% | ||
| Q2 24 | — | -1191.8% | ||
| Q1 24 | — | -2041.6% | ||
| Q3 23 | — | -1705.5% |
| Q4 25 | — | -22687.3% | ||
| Q3 25 | — | -9284.1% | ||
| Q1 25 | — | -2537.5% | ||
| Q4 24 | — | -2144.8% | ||
| Q3 24 | — | -1159.0% | ||
| Q2 24 | — | -945.1% | ||
| Q1 24 | — | -1573.0% | ||
| Q3 23 | — | -1597.7% |
| Q4 25 | — | $-1.53 | ||
| Q3 25 | — | $-0.97 | ||
| Q1 25 | — | $-0.82 | ||
| Q4 24 | — | $-0.76 | ||
| Q3 24 | — | $-0.74 | ||
| Q2 24 | — | $-0.51 | ||
| Q1 24 | — | $-0.54 | ||
| Q3 23 | — | $-3.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $404.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $493.4M |
| Total Assets | $13.1M | $530.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $404.3M | ||
| Q3 25 | — | $402.6M | ||
| Q1 25 | — | $263.2M | ||
| Q4 24 | — | $275.2M | ||
| Q3 24 | $2.5M | $281.1M | ||
| Q2 24 | — | $360.7M | ||
| Q1 24 | — | $377.0M | ||
| Q3 23 | — | $189.9M |
| Q4 25 | — | $493.4M | ||
| Q3 25 | — | $546.5M | ||
| Q1 25 | — | $328.6M | ||
| Q4 24 | — | $352.5M | ||
| Q3 24 | $6.0M | $337.9M | ||
| Q2 24 | — | $358.2M | ||
| Q1 24 | — | $372.7M | ||
| Q3 23 | — | $178.4M |
| Q4 25 | — | $530.9M | ||
| Q3 25 | — | $577.4M | ||
| Q1 25 | — | $348.6M | ||
| Q4 24 | — | $374.0M | ||
| Q3 24 | $13.1M | $354.2M | ||
| Q2 24 | — | $369.0M | ||
| Q1 24 | — | $382.5M | ||
| Q3 23 | — | $192.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-47.0M |
| Free Cash FlowOCF − Capex | $-1.6M | $-47.1M |
| FCF MarginFCF / Revenue | -392.9% | -16591.9% |
| Capex IntensityCapex / Revenue | 4.4% | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-47.0M | ||
| Q3 25 | — | $-30.6M | ||
| Q1 25 | — | $-27.6M | ||
| Q4 24 | — | $-27.4M | ||
| Q3 24 | $-1.6M | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-14.9M | ||
| Q3 23 | — | $-10.0M |
| Q4 25 | — | $-47.1M | ||
| Q3 25 | — | $-30.6M | ||
| Q1 25 | — | $-27.7M | ||
| Q4 24 | — | $-27.5M | ||
| Q3 24 | $-1.6M | $-21.3M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $-15.0M | ||
| Q3 23 | — | $-10.1M |
| Q4 25 | — | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q1 25 | — | -2377.8% | ||
| Q4 24 | — | -2072.0% | ||
| Q3 24 | -392.9% | -980.3% | ||
| Q2 24 | — | -780.7% | ||
| Q1 24 | — | -1713.2% | ||
| Q3 23 | — | -1088.4% |
| Q4 25 | — | 48.6% | ||
| Q3 25 | — | 1.3% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 4.4% | 1.2% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 3.7% | ||
| Q3 23 | — | 7.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
